Special Issue "Cell and Tissue-Based Formulations: from Design to Biomedical Applications"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".

Deadline for manuscript submissions: 31 March 2022.

Special Issue Editors

Dr. Beatriz Clares
E-Mail Website
Guest Editor
Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, Campus of Cartuja street s/n, University of Granada, 18071 Granada, Spain
Interests: nanoencapsulation; drug carrier; drug delivery
Special Issues, Collections and Topics in MDPI journals
Dr. Patricia Gálvez-Martín
E-Mail Website
Guest Editor
Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, University Campus of Cartuja, 18071 Granada, Spain
Interests: biomaterials; skin health; tissue engineering; cell therapy; legal regulatory aspect

Special Issue Information

Dear Colleagues,

We would like to invite you to contribute to this Special Issue, entitled “Cell and Tissue-Based Formulations: from Design to Biomedical Applications”.

The use of cells and tissues as therapeutic agents have emerged over the past decades in order to offers new therapeutic alternatives to conventional approaches, giving an opportunity to treat pathologies that have not been cured yet. In this regard, numerous advances have been made, including innovative methodologies such as bio-printing for the manufacture of three-dimensional structures.  However, the poor delivery and viability of the cells is very limiting and this task represents an area of intensive research. Formulation excipients and biomaterials can limit the quality, safety and efficacy of the product. It is therefore important to understand the efforts of the scientific community to develop defined formulations and to discuss the ability of formulation excipients to increase product quality and recovery during administration. In addition, the administration of living cells and tissues, whether they are differentiated adult cells, stem cells and cell derivatives for  biomedical application requires to know their mechanism of action and how they behave in the formulated product. Therefore, this special issue aims to cover different aspects involved in the design and development of cell and tissue based formulations for biomedical applications, and will include articles focused on the design, fabrication and characterization of different formulations loaded with living cells and/or tissue, ranging from suspensions, hydrogels, scaffolds, constructs until bioinks, as well as its latest advances in research and clinical.

The final goal is to facilitate the knowledge and scientific innovations into cell and tissue-based formulations in order to be used for biomedical applications.

Dr. Beatriz Clares
Dr. Patricia Gálvez-Martín
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Combination of Hyaluronan and Lyophilized Progenitor Cell Derivatives: Stabilization of Functional Hydrogel Products for Therapeutic Management of Tendinous Tissue Disorders
Pharmaceutics 2021, 13(12), 2196; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13122196 - 19 Dec 2021
Viewed by 550
Cultured progenitor cells and derivatives have been used in various homologous applications of cutaneous and musculoskeletal regenerative medicine. Active pharmaceutical ingredients (API) in the form of progenitor cell derivatives such as lysates and lyophilizates were shown to retain function in controlled cellular models [...] Read more.
Cultured progenitor cells and derivatives have been used in various homologous applications of cutaneous and musculoskeletal regenerative medicine. Active pharmaceutical ingredients (API) in the form of progenitor cell derivatives such as lysates and lyophilizates were shown to retain function in controlled cellular models of wound repair. On the other hand, hyaluronan-based hydrogels are widely used as functional vehicles in therapeutic products for tendon tissue disorders. The aim of this study was the experimental characterization of formulations containing progenitor tenocyte-derived APIs and hyaluronan, for the assessment of ingredient compatibility and stability in view of eventual therapeutic applications in tendinopathies. Lyophilized APIs were determined to contain relatively low quantities of proteins and growth factors, while being physicochemically stable and possessing significant intrinsic antioxidant properties. Physical and rheological quantifications of the combination formulas were performed after hydrogen peroxide challenge, outlining significantly improved evolutive viscoelasticity values in accelerated degradation settings. Thus, potent effects of physicochemical protection or stability enhancement of hyaluronan by the incorporated APIs were observed. Finally, combination formulas were found to be easily injectable into ex vivo tendon tissues, confirming their compatibility with further translational clinical approaches. Overall, this study provides the technical bases for the development of progenitor tenocyte derivative-based injectable therapeutic products or devices, to potentially be applied in tendinous tissue disorders. Full article
Show Figures

Figure 1

Back to TopTop